Cargando…

Distinct blood inflammatory biomarker clusters stratify host phenotypes during the middle phase of COVID-19

The associations between clinical phenotypes of coronavirus disease 2019 (COVID-19) and the host inflammatory response during the transition from peak illness to convalescence are not yet well understood. Blood plasma samples were collected from 129 adult SARS-CoV-2 positive inpatient and outpatient...

Descripción completa

Detalles Bibliográficos
Autores principales:	Blair, Paul W., Brandsma, Joost, Chenoweth, Josh, Richard, Stephanie A., Epsi, Nusrat J., Mehta, Rittal, Striegel, Deborah, Clemens, Emily G., Alharthi, Sultanah, Lindholm, David A., Maves, Ryan C., Larson, Derek T., Mende, Katrin, Colombo, Rhonda E., Ganesan, Anuradha, Lalani, Tahaniyat, Colombo, Christopher J., Malloy, Allison A., Snow, Andrew L., Schully, Kevin L., Lanteri, Charlotte, Simons, Mark P., Dumler, John S., Tribble, David, Burgess, Timothy, Pollett, Simon, Agan, Brian K., Clark, Danielle V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9795438/ https://www.ncbi.nlm.nih.gov/pubmed/36577783 http://dx.doi.org/10.1038/s41598-022-26965-7

Ejemplares similares

438. Phenotypic Differences Between Distinct Immune Biomarker Clusters During the ‘Hyperinflammatory’ Middle-Phase of COVID-19
por: Blair, Paul W, et al.
Publicado: (2021)

458. A Machine Learning Approach Identifies Distinct Early-Symptom Cluster Phenotypes Which Correlate with Severe SARS-CoV-2 Outcomes
por: Epsi, Nusrat J, et al.
Publicado: (2021)

508. Biomarker elevation during COVID-19: Differences between ambulatory and hospitalized individuals
por: Blair, Paul W, et al.
Publicado: (2020)

34. Long-term clinical outcomes following SARS-CoV-2 infection include persistent symptoms and cardiovascular disease beyond 3 months post-infection
por: Richard, Stephanie A, et al.
Publicado: (2021)

1352. A Precision Medicine Approach to Predicting “Long COVID” through Machine Learning Analysis of Whole Blood Transcriptome Data
por: Epsi, Nusrat J, et al.
Publicado: (2023)

Clinical, Immunological, and Virological SARS-CoV-2 Phenotypes in Obese and Nonobese Military Health System Beneficiaries
por: Epsi, Nusrat J, et al.
Publicado: (2021)

Anatomical Site, Viral Ribonucleic Acid Abundance, and Time of Sampling Correlate With Molecular Detection of Severe Acute Respiratory Syndrome Coronavirus 2 During Infection
por: Lantry, F Julian, et al.
Publicado: (2021)

337. SARS-CoV-2 Viral Load Does Not Predict Incident Venous Thromboembolism in COVID-19
por: Pollett, Simon, et al.
Publicado: (2021)

A machine learning approach identifies distinct early-symptom cluster phenotypes which correlate with hospitalization, failure to return to activities, and prolonged COVID-19 symptoms
por: Epsi, Nusrat J., et al.
Publicado: (2023)

434. Characteristics and long-term outcomes of SARS-CoV-2 associated myocarditis cases in the Military Health System
por: Pollett, Simon, et al.
Publicado: (2023)

COVID-19 Patient-Reported Symptoms Using FLU-PRO Plus in a Cohort Study: Associations With Infecting Genotype, Vaccine History, and Return to Health
por: Richard, Stephanie A, et al.
Publicado: (2022)

437. Does “Long COVID” Resolve by One Year in U.S. Military Health System Beneficiaries?
por: Richard, Stephanie A, et al.
Publicado: (2023)

Persistent COVID-19 Symptoms at 6 Months After Onset and the Role of Vaccination Before or After SARS-CoV-2 Infection
por: Richard, Stephanie A., et al.
Publicado: (2023)

80. SARS-CoV-2 infection is associated with decreased reported physical fitness in a US military longitudinal cohort
por: Richard, Stephanie A, et al.
Publicado: (2022)

1263. Anti-Retroviral (ART) Success in an Active Duty Military Cohort from 2002 to 2016, A Model for Ending the HIV Epidemic in the United States
por: Schofield, Christina, et al.
Publicado: (2019)

COVID-19 Outcomes Among US Military Health System Beneficiaries Include Complications Across Multiple Organ Systems and Substantial Functional Impairment
por: Richard, Stephanie A, et al.
Publicado: (2021)

1056. Correlates of Omicron SARS-CoV-2 viral load: diagnostic and clinical implications
por: Pollett, Simon, et al.
Publicado: (2022)

185. Despite the Availability of Free Testing and Care Testing for Extragenital Sexually Transmitted Infections in a Cohort of Hiv-infected Department of Defense Beneficiaries Is Low and Similar to the Rates Observed Nationwide
por: Ganesan, Anuradha, et al.
Publicado: (2020)

The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA Vaccine-Breakthrough Infection Phenotype Includes Significant Symptoms, Live Virus Shedding, and Viral Genetic Diversity
por: Pollett, Simon D, et al.
Publicado: (2021)

450. Type I Interferon Autoantibodies Are Detected in Those with Critical COVID-19, Including a Young Female Patient
por: Yee, Debra, et al.
Publicado: (2021)

441. Prior SARS-CoV-2 Diagnosis is a Risk Factor for Herpes Zoster in Younger Adults: A Nested Case-control Study in the EPICC Cohort
por: Schmidt, Kat, et al.
Publicado: (2023)

387. Understanding the Impact of COVID-19 on Cognitive Function Using a Scalable, App-based, Self-administered Tool in the Military
por: Andronescu, Liana, et al.
Publicado: (2023)

1014. Factors Associated with Switching from Tenofovir Diproxil Phosphate to a Tenofovir Alafenamide Based Regimen in a Cohort with Unrestricted Access to Care and Medications
por: Ganesan, Anuradha, et al.
Publicado: (2020)

Risk Factors Associated With Chronic Liver Enzyme Elevation in Persons With HIV Without Hepatitis B or C Coinfection in the Combination Antiretroviral Therapy Era
por: Wood, Shannon, et al.
Publicado: (2021)

An Analysis of SARS-CoV-2 Vaccine Reactogenicity: Variation by Type, Dose, and History, Severity, and Recency of Prior SARS-CoV-2 Infection
por: Scher, Ann I, et al.
Publicado: (2022)

461. Classical Antigen Presenting Cell Activation Correlates with T Cell Immunity and COVID-19 Severity
por: Lu, Zhongyan, et al.
Publicado: (2021)

726. Operational Impact of Infectious Disease Threats During Military Travel
por: Boatwright, Michael A, et al.
Publicado: (2021)

Antigenic cartography of well-characterized human sera shows SARS-CoV-2 neutralization differences based on infection and vaccination history
por: Wang, Wei, et al.
Publicado: (2022)

Assessing the use of a micro-sampling device for measuring blood protein levels in healthy subjects and COVID-19 patients
por: Brandsma, Joost, et al.
Publicado: (2022)

2800. Pragmatic Assessment of Influenza Vaccine Effectiveness in the DoD (PAIVED): Influenza-Like-Illness Rates in Year 1
por: Schofield, Christina, et al.
Publicado: (2019)

2751. Pragmatic Assessment of Influenza Vaccine Effectiveness in the DoD (PAIVED): Methods
por: Burgess, Timothy, et al.
Publicado: (2019)

2749. Disparities in Healthcare Seeking Behaviors in the Pragmatic Assessment of Influenza Vaccine Effectiveness in the DoD (PAIVED) Study
por: Schofield, Christina, et al.
Publicado: (2019)

2757. Pragmatic Assessment of Influenza Vaccine Effectiveness in the DoD (PAIVED): Immunogenicity Sub-Study
por: Colombo, Rhonda, et al.
Publicado: (2019)

COVID-19 CHRONIC IMPAIRMENT WITH PULMONARY SYMPTOMS
por: GOERTZEN, STEPHEN M, et al.
Publicado: (2022)

Effects of human immunodeficiency virus status on symptom severity in influenza-like illness in an otherwise healthy adult outpatient cohort
por: Colombo, Rhonda E, et al.
Publicado: (2021)

477. Characteristics and Long-Term Outcomes of Cardiac Complications of SARS-CoV-2 in Youth: Results from the EPICC YES C3 Prospective Longitudinal Cohort Module
por: Jones, Milissa U, et al.
Publicado: (2023)

SARS-CoV-2 BA.1 variant is neutralized by vaccine booster-elicited serum, but evades most convalescent serum and therapeutic antibodies
por: Lusvarghi, Sabrina, et al.
Publicado: (2022)

SARS-CoV-2 Omicron neutralization by therapeutic antibodies, convalescent sera, and post-mRNA vaccine booster
por: Lusvarghi, Sabrina, et al.
Publicado: (2021)

571. In a Well-Characterized Cohort with Universal Access to Care and Medications Racial Disparities in HIV Virologic Outcomes Are No Longer Observed
por: Ganesan, Anuradha, et al.
Publicado: (2018)

2248. Changes in Lipid Profiles for Patients to Tenofovir Alafenamide (TAF)-Containing Regimens: Perspectives from a Military HIV-Positive Cohort
por: Ewers, Evan, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_1j30d7blbrf7n3qcibvkdhempq